Dr. Herbst Discusses New Immunotherapy Agents for Lung Cancer

Roy S. Herbst, MD, PhD
Published: Wednesday, Aug 20, 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses new immunotherapy agents showing potential as treatment options for patients with lung cancer.

Herbst says these agents are demonstrating response rates of up to 20% in unselected patients with refractory lung cancer. Response rates will increase to 50% if patients are selected for treatment with biomarkers. However, Herbst says, biomarker development is still in the early stages and more research needs to be conducted to fully utilize this approach.

For the patients that don’t seem to be responding to immunotherapy treatment, Herbst says researchers are working to understand why this is occurring and conducting trials to see if there are ways that the immune system can be enhanced so that these agents will work.

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses new immunotherapy agents showing potential as treatment options for patients with lung cancer.

Herbst says these agents are demonstrating response rates of up to 20% in unselected patients with refractory lung cancer. Response rates will increase to 50% if patients are selected for treatment with biomarkers. However, Herbst says, biomarker development is still in the early stages and more research needs to be conducted to fully utilize this approach.

For the patients that don’t seem to be responding to immunotherapy treatment, Herbst says researchers are working to understand why this is occurring and conducting trials to see if there are ways that the immune system can be enhanced so that these agents will work.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x